11th treatment shown to reduce risk in
January 2021
No treatment is 100% effective. Protocols
combine complementary and synergistic treatments. * >10%
efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for
60+ treatments. c19early.org
|
|
risk of symptomatic case, 34.1% lower, RR 0.66, p = 0.006, treatment 37 of 89 (41.6%), control 53 of 84 (63.1%), NNT 4.6, any symptom.
|
|
risk of symptomatic case, 97.3% lower, RR 0.03, p < 0.001, treatment 1 of 89 (1.1%), control 35 of 84 (41.7%), NNT 2.5, fever.
|
|
risk of symptomatic case, 65.7% lower, RR 0.34, p = 0.06, treatment 4 of 89 (4.5%), control 11 of 84 (13.1%), NNT 12, chest pain.
|
|
risk of symptomatic case, 62.2% lower, RR 0.38, p = 0.10, treatment 4 of 89 (4.5%), control 10 of 84 (11.9%), NNT 13, loss of taste/smell.
|
|
risk of symptomatic case, 26.0% lower, RR 0.74, p = 0.16, treatment 29 of 89 (32.6%), control 37 of 84 (44.0%), NNT 8.7, muscle ache.
|
|
risk of symptomatic case, 6.2% higher, RR 1.06, p = 1.00, treatment 9 of 89 (10.1%), control 8 of 84 (9.5%), chills.
|
|
risk of symptomatic case, 79.0% lower, RR 0.21, p = 0.001, treatment 4 of 89 (4.5%), control 18 of 84 (21.4%), NNT 5.9, cough.
|
|
risk of symptomatic case, 76.4% lower, RR 0.24, p < 0.001, treatment 5 of 89 (5.6%), control 20 of 84 (23.8%), NNT 5.5, headache.
|
|
risk of symptomatic case, 98.1% lower, RR 0.02, p < 0.001, treatment 0 of 89 (0.0%), control 25 of 84 (29.8%), NNT 3.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), vomiting.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
